Fadlo R. Khuri (Arabic: فضلو خوري) is a Lebanese-American physician, researcher, and academic administrator, and the 16th president of the American University of Beirut (AUB) since 2015.

[1] A specialist in oncology, he previously held prominent positions in medical research and academic administration in the United States before assuming leadership at AUB.

He was professor and chair of hematology and medical oncology at Emory University’s School of Medicine[4] and was deputy director of the Winship Cancer Institute in Georgia.

[5] Among his most significant and highly cited publications is a controlled trial of ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.

His clinical cancer research also includes a Phase I study on the farnesyltransferase inhibitor lonafarnib in combination with paclitaxel for solid tumors.